There are 2867 resources available
735MO - Updated safety and efficacy from SURPASS, the phase I trial of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in previously treated patients with unresectable or metastatic tumors
Presenter: David S Hong
Session: Mini Oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
214MO - Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study
Presenter: Frederik Marmé
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
736MO - Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS)
Presenter: Chrisann Kyi
Session: Mini Oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
215MO - ICON – a randomized phase IIb study evaluating chemotherapy combined with ipilimumab and nivolumab in metastatic hormone receptor-positive breast cancer
Presenter: Jon Amund Kyte
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant 1204MO and 1205MO
Presenter: Florian Lordick
Session: Mini Oral session: GI, upper digestive
Resources:
Slides
Webcast
737MO - EpCAM-targeted CAR-T cell therapy in patients with advanced colorectal and gastric cancers
Presenter: Weijia Fang
Session: Mini Oral session: Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
216MO - A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) vs weekly paclitaxel (P) as first- or second-line treatment in patients (pts) with ER+/HER2- metastatic breast cancer (MBC): The METEORA-II trial (IBCSG 54-16)
Presenter: Elisabetta Munzone
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant 213MO, 214MO, 215MO and 216MO
Presenter: Shom Goel
Session: Mini Oral session: Breast cancer, metastatic
Resources:
Slides
Webcast
Invited Discussant 735MO, 736MO and 737MO
Presenter: Alessandra Curioni
Session: Mini Oral session: Investigational immunotherapy
Resources:
Slides
Webcast
Can novel radiotherapy techniques pave the way for new combinations?
Presenter: Eric Deutsch
Session: How can we collaborate better as a multidisciplinary team to develop novel therapeutics?
Resources:
Slides
Webcast